Mimosa Nguyen1, Yvette Mukaneza1, Mélanie Tremblay1, Geneviève Huard2, An Tang1,2,3, Christopher F Rose1,4, Chantal Bémeur1,5. 1. Centre de recherche du Centre hospitalier de l'Université de Montréal, Montréal, Québec, Canada. 2. Centre hospitalier de l'Université de Montréal, Montréal, Québec, Canada. 3. Department of Radiology, Radiation Oncology and Nuclear Medicine, Université de Montréal, Montréal, Québec, Canada. 4. Department of Medicine, Université de Montréal, Montréal, Québec, Canada. 5. Department of Nutrition, Université de Montréal, Montréal, Québec, Canada.
Abstract
Background: Liver transplantation (LT) is the only curative treatment for cirrhosis. However, the presence of complications can impact outcomes following LT. Sarcopenia, or muscle mass loss, is highly prevalent in patients with cirrhosis and is associated with longer hospitalization stays and a higher infection rate post-surgery. We aimed to identify patients at higher risk of early sarcopenia post-LT. Methods: This retrospective study included 79 cirrhotic patients who underwent LT. Muscle mass was evaluated using the third lumbar spine vertebra skeletal muscle index (SMI) and sarcopenia was defined using established cut-off values. Computerized tomography (CT) scans performed within a six-month peri-operative period (three months pre- and post-LT) were included in the study. Complications and comorbidities were collected and correlated to SMI post-LT and predictive models for SMI post-LT were constructed. Results: The overall prevalence of sarcopenia was 46% and 62% before and after LT, respectively. Newly developed sarcopenia was found in 42% of patients. Post-LT sarcopenia was associated with longer hospital stays (54±37 versus 29±10 days, p = 0.002), higher number of infection (3±1 versus 1±2, p = 0.027), and greater number of complications (5±2 versus 3±2, p < 0.001) compared to absence of sarcopenia. Multivariate analyses showed that the SMI post-LT was independently associated with pre-LT renal function markers, the glomerular filtration rate (GFR) and creatinine (Model 1, GFR: β = 0.33; 95% CI 0.04-0.17; p = 0.003; Model 2, Creatinine: β = -0.29; 95% CI -0.10 to -0.02; p = 0.009). Conclusions: The present study highlights the potential role of renal dysfunction in the development and persistence of sarcopenia after LT.
Background: Liver transplantation (LT) is the only curative treatment for cirrhosis. However, the presence of complications can impact outcomes following LT. Sarcopenia, or muscle mass loss, is highly prevalent in patients with cirrhosis and is associated with longer hospitalization stays and a higher infection rate post-surgery. We aimed to identify patients at higher risk of early sarcopenia post-LT. Methods: This retrospective study included 79 cirrhotic patients who underwent LT. Muscle mass was evaluated using the third lumbar spine vertebra skeletal muscle index (SMI) and sarcopenia was defined using established cut-off values. Computerized tomography (CT) scans performed within a six-month peri-operative period (three months pre- and post-LT) were included in the study. Complications and comorbidities were collected and correlated to SMI post-LT and predictive models for SMI post-LT were constructed. Results: The overall prevalence of sarcopenia was 46% and 62% before and after LT, respectively. Newly developed sarcopenia was found in 42% of patients. Post-LT sarcopenia was associated with longer hospital stays (54±37 versus 29±10 days, p = 0.002), higher number of infection (3±1 versus 1±2, p = 0.027), and greater number of complications (5±2 versus 3±2, p < 0.001) compared to absence of sarcopenia. Multivariate analyses showed that the SMI post-LT was independently associated with pre-LT renal function markers, the glomerular filtration rate (GFR) and creatinine (Model 1, GFR: β = 0.33; 95% CI 0.04-0.17; p = 0.003; Model 2, Creatinine: β = -0.29; 95% CI -0.10 to -0.02; p = 0.009). Conclusions: The present study highlights the potential role of renal dysfunction in the development and persistence of sarcopenia after LT.
Authors: Puneeta Tandon; Michael Ney; Ivana Irwin; Mang M Ma; Leah Gramlich; Vincent G Bain; Nina Esfandiari; Vickie Baracos; Aldo J Montano-Loza; Robert P Myers Journal: Liver Transpl Date: 2012-10 Impact factor: 5.799
Authors: Jared M Dickinson; Christopher S Fry; Micah J Drummond; David M Gundermann; Dillon K Walker; Erin L Glynn; Kyle L Timmerman; Shaheen Dhanani; Elena Volpi; Blake B Rasmussen Journal: J Nutr Date: 2011-03-23 Impact factor: 4.798
Authors: P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim Journal: Hepatology Date: 2001-02 Impact factor: 17.425
Authors: Jorge L Gamboa; Frederic T Billings; Matthew T Bojanowski; Laura A Gilliam; Chang Yu; Baback Roshanravan; L Jackson Roberts; Jonathan Himmelfarb; T Alp Ikizler; Nancy J Brown Journal: Physiol Rep Date: 2016-05
Authors: Alfonso J Cruz-Jentoft; Gülistan Bahat; Jürgen Bauer; Yves Boirie; Olivier Bruyère; Tommy Cederholm; Cyrus Cooper; Francesco Landi; Yves Rolland; Avan Aihie Sayer; Stéphane M Schneider; Cornel C Sieber; Eva Topinkova; Maurits Vandewoude; Marjolein Visser; Mauro Zamboni Journal: Age Ageing Date: 2019-01-01 Impact factor: 10.668